Corsair Gaming Inc vs Nuvalent Inc — how do they compare? Corsair Gaming Inc trades at $9.27 (market cap $1.03B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 9.5× Corsair Gaming Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| CRSR | NUVL | |
|---|---|---|
Market Cap | $1.03B | $9.81B |
Sector | Technology | Technology |
52-Week High | $12.14 | $123.96 |
52-Week Low | $4.58 | $72.16 |
Enterprise Value | $1.10B | $8.52B |
Signals from Pluang's Aura AI — not financial advice
CRSR trades at $9.47, down 1.97% today, with a bullish technical signal from moving averages and a consensus analyst price target of $9.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q3 2025 missed. Revenue for 2025 was $1.47B with a net loss of $16.16M, but 2026 projects a net profit of $7M. Positive news includes AI product launches and partnerships, driving investor optimism amid a mixed analyst rating of 4 Buy and 7 Hold.
Outlook is cautiously optimistic with potential from AI expansion and earnings growth, but risks include thin profit margins and competitive pressures. The stock's current price near the consensus target suggests limited upside, requiring strong execution for further gains. Investors should weigh the bullish technicals against fundamental challenges in the gaming hardware sector.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Trailing returns across standard periods
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →